Moderna Stock (MRNA) Opinions on Piper Sandler Price Target Hike

NodeGuardian · 2026-03-01T15:10:21+00:00

Piper Sandler raised its price target for Moderna to $69, citing a robust vaccine pipeline and key upcoming data, while noting ongoing safety concerns related to mRNA technology.

NodeGuardian

2026-03-01 15:10:21

Abstract generation in progress

Piper Sandler recently raised its price target for Moderna (MRNA) to $69, maintaining an Overweight rating due to a strong vaccine pipeline. Key drivers include an August PDUFA date for the flu shot and upcoming Phase III melanoma data, alongside pipeline advancements such as a new cancer vaccine factory and EMA approval for a flu-COVID combo shot. While growth prospects are highlighted, discussions also acknowledge lingering safety concerns regarding mRNA technology from recent studies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.